Pancreatic Cancer Research

ResearcherKumamoto UniversityActive in the last 2 years

Masaaki Iwatsuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0886-4618; OpenAlex author ID A5060949471, A5133702688. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2026: 12 papers

Papers 12

  1. Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for Pancreatic Cancer. Last author DOI 10.1002/ags3.70297↗
  2. High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection. Last author DOI 10.1002/jhbp.70032↗
  3. A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. Last author DOI 10.1007/s12328-025-02256-2↗
  4. A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy. Last author DOI 10.1007/s12328-026-02359-4↗
  5. The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreatectomy. Last author DOI 10.1016/j.pan.2026.04.008↗
  6. Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… Last author DOI 10.1097/mpa.0000000000002641↗
  7. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  8. ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18960-9↗
  9. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  10. Proinsulin Promotes Tumor Development in the PANC-1 Pancreatic Adenocarcinoma Cell Line. Co-author DOI 10.21873/anticanres.18130↗
  11. Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.18442↗
  12. A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab. Last author DOI 10.70352/scrj.cr.26-0273↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 9 shared papers, 2026 · strength 2.57
  2. Yuki Kitano · 8 shared papers, 2026 · strength 2.24
  3. Hirohisa Okabe · 8 shared papers, 2026 · strength 2.24
  4. Shinsei Yumoto · 5 shared papers, 2026 · strength 1.36
  5. Tatsunori Miyata · 5 shared papers, 2026 · strength 1.35
  6. Shigeki Nakagawa · 4 shared papers, 2026 · strength 1.10
  7. Takanobu Yamao · 3 shared papers, 2026 · strength 0.86
  8. Toru Takematsu · 3 shared papers, 2026 · strength 0.84
  9. Rumi Itoyama · 3 shared papers, 2026 · strength 0.83
  10. Yoshihiro Ono · 3 shared papers, 2026 · strength 0.78
  11. Atsushi Oba · 3 shared papers, 2026 · strength 0.78
  12. Takashi Matsumoto · 2 shared papers, 2026 · strength 0.57
  13. Yosuke Inoue · 2 shared papers, 2026 · strength 0.54
  14. Yuki Adachi · 2 shared papers, 2026 · strength 0.53
  15. Takashi Sasaki · 2 shared papers, 2026 · strength 0.48
  16. Aya Maekawa · 2 shared papers, 2026 · strength 0.48
  17. Masato Ozaka · 2 shared papers, 2026 · strength 0.48
  18. Tomotaka Kato · 2 shared papers, 2026 · strength 0.48
  19. Naoki Sasahira · 2 shared papers, 2026 · strength 0.48
  20. Kazuya Yamagata · 1 shared paper, 2026 · strength 0.33
  21. Tomonori Tsuyama · 1 shared paper, 2026 · strength 0.33
  22. Hirohisa Okabe · 1 shared paper, 2026 · strength 0.33
  23. Yu Takahashi · 1 shared paper, 2026 · strength 0.30
  24. Kazuto Takata · 1 shared paper, 2026 · strength 0.30
  25. Yasuhito Tanaka · 1 shared paper, 2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.